Author: Dewpoint Therapeutics

Posted Date:

February 11, 2026

Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate

Dewpoint Therapeutics

February 11, 2026
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

Dewpoint Therapeutics

February 4, 2026